Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:42:14.400Z.
Calculation as of: 2026-10-06T13:42:14.400Z.
Quote observation: 2026-10-06T13:38:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 26b9d76e1867df839f3ea79fd47ae1c5236575fa33f8c6240ddbf9d3395e1dfe
PE RATIO
N/A
Market Cap
$38.20M
PE Ratio
N/A
TTM Avg
328.93
3Y Avg
271.56
5Y Avg
151.89
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $36.61M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $37.59M | N/A | 241.49 | 241.49 | 115.68 |
| BriaCell Therapeutics Corp. (BCTX)vs › | $36.70M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.20M | N/A | 328.93 | 271.56 | 151.89 |
| Edesa Biotech, Inc. (EDSA)vs › | $38.53M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $37.40M | N/A | 14.70 | 37.22 | 37.36 |
| Elutia Inc (ELUT)vs › | $34.93M | 0.84 | 1.13 | 1.13 | 1.13 |
| Incannex Healthcare Limited (IXHL)vs › | $39.48M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $34.18M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.92
Forward EPS (Est.)
$-1.88
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
